Jefferies Financial Group Reiterates “Buy” Rating for BioNTech (NASDAQ:BNTX)

BioNTech (NASDAQ:BNTX)‘s stock had its “buy” rating reiterated by investment analysts at Jefferies Financial Group in a report released on Monday,MarketScreener reports.

BNTX has been the topic of several other research reports. HC Wainwright reaffirmed a “buy” rating and set a $136.00 target price on shares of BioNTech in a research report on Monday, September 8th. JPMorgan Chase & Co. reduced their price target on BioNTech from $121.00 to $120.00 and set a “neutral” rating on the stock in a research report on Thursday, October 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of BioNTech in a research report on Tuesday, October 14th. Cowen reaffirmed a “hold” rating on shares of BioNTech in a research report on Monday. Finally, Wells Fargo & Company set a $150.00 price target on BioNTech and gave the company an “overweight” rating in a research note on Tuesday, August 5th. Eleven analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, BioNTech presently has an average rating of “Moderate Buy” and a consensus price target of $134.17.

BioNTech Stock Up 0.0%

Shares of NASDAQ:BNTX opened at $103.96 on Monday. The business’s 50 day moving average is $102.50 and its 200 day moving average is $105.01. The stock has a market cap of $23.41 billion, a P/E ratio of -64.97 and a beta of 1.45. BioNTech has a 52-week low of $81.20 and a 52-week high of $129.27. The company has a quick ratio of 8.48, a current ratio of 8.61 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Monday, November 3rd. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of $0.75 by ($0.89). The firm had revenue of $1.78 billion during the quarter, compared to analysts’ expectations of $1.21 billion. BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.BioNTech’s quarterly revenue was up 22.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.81 earnings per share. BioNTech has set its FY 2025 guidance at EPS. Sell-side analysts predict that BioNTech will post -3.88 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Banque Cantonale Vaudoise purchased a new stake in BioNTech in the first quarter valued at $36,000. Financial Consulate Inc. acquired a new position in shares of BioNTech in the 3rd quarter valued at about $36,000. LRI Investments LLC boosted its stake in shares of BioNTech by 234.6% in the second quarter. LRI Investments LLC now owns 445 shares of the company’s stock worth $47,000 after buying an additional 312 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in BioNTech by 118.2% during the second quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock worth $60,000 after acquiring an additional 305 shares during the period. Finally, Hantz Financial Services Inc. raised its position in BioNTech by 472.0% during the second quarter. Hantz Financial Services Inc. now owns 572 shares of the company’s stock valued at $61,000 after acquiring an additional 472 shares in the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.